GLEOLAN.COM: Keyword Density Checker

Total words: 1687 | 2-word phrases: 443 | 3-word phrases: 484 | 4-word phrases: 495

PAGE INFO

Title	Try to keep the title under 60 characters (38 characters) Gleolan - Optical Glioma Imaging Agent
Description	Try to keep the meta description between 50 - 160 characters (104 characters) An optical imaging agent indicated in patients with glioma. Visualize Brain Cancer in a Different Light.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (28 characters) For Healthcare Professionals

#	Keyword	Frequency	Density
1	in the	7	1.58%
2	of patients	6	1.35%
3	in patients	5	1.13%
4	patients with	5	1.13%
5	the first	4	0.90%
6	in 1	4	0.90%
7	visualization of	3	0.68%
8	do not	3	0.68%
9	occurred in	3	0.68%
10	hypersensitivity reactions	3	0.68%
11	1 of	3	0.68%
12	patients in	3	0.68%
13	to the	3	0.68%
14	prescribing information	3	0.68%
15	in a	3	0.68%
16	after surgery	3	0.68%
17	chronic types	2	0.45%
18	acute or	2	0.45%
19	porphyrins acute	2	0.45%
20	of malignant	2	0.45%

#	Keyword	Frequency	Density
1	in patients with	4	0.83%
2	in the first	3	0.62%
3	of patients in	3	0.62%
4	1 of patients	3	0.62%
5	in 1 of	3	0.62%
6	within the first	2	0.41%
7	the first week	2	0.41%
8	first week after	2	0.41%
9	week after surgery	2	0.41%
10	visualization of malignant	2	0.41%
11	occurred in 1	2	0.41%
12	or porphyrins acute	2	0.41%
13	do not use	2	0.41%
14	not use gleolan	2	0.41%
15	use gleolan in	2	0.41%
16	gleolan in patients	2	0.41%
17	hypersensitivity to aminolevulinic	2	0.41%
18	acid ala or	2	0.41%
19	ala or porphyrins	2	0.41%
20	porphyrins acute or	2	0.41%
21	chronic types of	2	0.41%
22	patients with glioma	2	0.41%
23	types of porphyria	2	0.41%
24	occurring in 1	2	0.41%
25	patients in the	2	0.41%
26	in the week	1	0.21%
27	patients randomized to	1	0.21%
28	control arm an	1	0.21%
29	compared to the	1	0.21%
30	arm compared to	1	0.21%

#	Keyword	Frequency	Density
1	1 of patients in	3	0.61%
2	in 1 of patients	3	0.61%
3	do not use gleolan	2	0.40%
4	in patients with glioma	2	0.40%
5	gleolan in patients with	2	0.40%
6	acid ala or porphyrins	2	0.40%
7	ala or porphyrins acute	2	0.40%
8	or porphyrins acute or	2	0.40%
9	chronic types of porphyria	2	0.40%
10	not use gleolan in	2	0.40%
11	first week after surgery	2	0.40%
12	the first week after	2	0.40%
13	within the first week	2	0.40%
14	of patients in the	2	0.40%
15	occurring in 1 of	2	0.40%
16	use gleolan in patients	2	0.40%
17	and equipment readily available	1	0.20%
18	after surgery in a	1	0.20%
19	neurologic adverse events in	1	0.20%
20	serious neurologic adverse events	1	0.20%
21	trial the numbers of	1	0.20%
22	clinical trial the numbers	1	0.20%
23	randomized clinical trial the	1	0.20%
24	a randomized clinical trial	1	0.20%
25	in a randomized clinical	1	0.20%
26	surgery in a randomized	1	0.20%
27	weeks after surgery in	1	0.20%
28	events in the post	1	0.20%
29	in the first 6	1	0.20%
30	patients in the first	1	0.20%
31	occurred in 1 of	1	0.20%
32	edema occurred in 1	1	0.20%
33	brain edema occurred in	1	0.20%
34	11 brain edema occurred	1	0.20%
35	hypoesthesia 11 brain edema	1	0.20%
36	19 monoparesis 13 and	1	0.20%
37	adverse events in the	1	0.20%
38	in the post operative	1	0.20%
39	19 hemiplegia 19 monoparesis	1	0.20%
40	hypersensitivity reactions including serious	1	0.20%

#	URL	Whois	Check
1	https://20173990.fs1.hubspotusercontent-na1.net/hubfs/20173990/Documents/package-insert-03-2022.pdf	Whois	hubspotusercontent-na1.net
2	https://20173990.fs1.hubspotusercontent-na1.net/hubfs/20173990/Documents/package-insert-03-2022.pdf	Whois	hubspotusercontent-na1.net
3	https://20173990.fs1.hubspotusercontent-na1.net/hubfs/20173990/Documents/package-insert-03-2022.pdf	Whois	hubspotusercontent-na1.net
4	https://www.medexus.com/en_US	Whois	medexus.com